The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres

Advanced Drug Delivery Reviews

Volumn 16, Issue 2-3, 1995, Pages 215-233

  Gref, R ^a   Domb, A ^b   Quellec, P ^a   Blunk, T ^c   Muller R H ^d   Verbavatz, J M ^e   Langer, R ^f  

^a LAB DE CHIM PHYS MACROMOLECULAIRE   (France)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c UNIVERSITY OF KIEL   (Germany)

^d FREIE UNIVERSITÄT BERLIN   (Germany)

^e CEA SACLAY   (France)

^f MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Biodegradable polymers; Hydrophilic coating; Intravenous drug administration; Long circulating nanoparticles; Polyethylene glycol; Reduced liver accumulation

Indexed keywords

BLOCK COPOLYMERS; COATINGS; DRUG PRODUCTS; MOLECULAR WEIGHT; PARTICLES (PARTICULATE MATTER); PHARMACOKINETICS; POLYETHYLENE GLYCOLS; SURFACE PROPERTIES; TISSUE;

CONTROLLED INTRAVENOUS DRUG DELIVERY; INTRAVENOUS DRUG ADMINISTRATION; LIVER; LONG-CIRCULATING NANOPARTICLES; NANOSPHERES; REDUCED LIVER ACCUMULATION; RETICULO-ENDOTHELIAL SYSTEM; SPLEEN;

CONTROLLED DRUG DELIVERY;

CARMUSTINE; CHOLIC ACID; COPOLYMER; DEOXYCHOLIC ACID; DRUG CARRIER; GLYCOCHOLIC ACID; IBUPROFEN; LIDOCAINE; MACROGOL; NANOPARTICLE; OCTYL GLUCOSIDE; OLIGONUCLEOTIDE; POLYMER; POLYVINYL ALCOHOL; PREDNISOLONE; SURFACTANT; TAUROCHOLIC ACID;

BIODEGRADATION; CIRCULATION TIME; DRUG ADMINISTRATION; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG RELEASE; ENCAPSULATION; HYDROPHILICITY; HYDROPHOBICITY; INTRAVENOUS DRUG ADMINISTRATION; MACROPHAGE; NONHUMAN; OPSONIZATION; PHARMACEUTICS; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; REVIEW;

EID: 0029360414     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0169-409X(95)00026-4     Document Type: Review

References (98)

1. Bioavailability of macromolecular drugs and its control
2. Development of a nanoparticle controlled-release formulation for human use
3. Nanoparticles
4. Physiology and physiopatholgy of the reticuloendothelial system
5. The organ distribution and circulation time of intravenously injected colloidal carriers sterically stabilized with a block copolymer-Poloxamine 908
6. Intravenous contrast echocardiography with use of sonicated albumin in humans: systolic dissapearance of left ventricular contrast after transpulmonary transmission
7. 14C-poly(lactic acid) nanoparticles coated with albumin after parenteral administration to rats
8. Distribution kinetics and elimination of radioactivity after intravenous and intramuscular injection of savoxepine loaded poly (dl-lactic acid) nanospheres to rats
9. dl-lactide-co-glycolide) nanoparticles after intravenous and oral administration to mice
10. 14C-methacrylate) nanoparticles radioactivity after injection in rats and mice
11. Biodegradable microspheres. IV. Factors affecting the distribution and degradation of polyacryl starch microparticles
12. Cellular uptake of a fluid-phase marker by human neutrophils from solutions and liposomes
13. The role of complements C3 and C5 in the phagocytosis of liposomes by human neutrophils
14. 14C-poly(methyl methacrylate) nanoparticles
15. Amphiphatic polyethyleneglycols effectively prolong the circulation time of liposomes
16. Liposomes for the sustained drug release in vivo
17. How do hydrophilic surfaces determine liposome fate in vivo?
18. Design and properties of particulate carriers for intravascular administration
19. The use of glycolipids and hydrophilic polymers in avoiding rapid uptake of liposomes by the mononuclear phagocyte system
20. Camouflage nanospheres: a new approach to bypassing phagocytic blood clearance by surface modified particulate carriers
21. Biodegradable long-circulating nanospheres
22. Poly(ethylene glycol)-coated biodegradable nanospheres for intravenous drug administration
23. Biodegradable PEG-coated stealth nanospheres
24. Drug delivery from bioerodible polymers: systemic and intravenous administration, in proteins formulation and peptide delivery
25. PEG-coated nanospheres for intravenous drug delivery and targeting
26. Poly(ethylene glycol)-coated injectable long-circulating nanospheres prepared from amphiphatic bioerodible polymers
27. PEG-coated nanospheres for intravenous administration
28. PEG-polyester and PEG-polyanhydride diblock and multiblock copolymers for PEG-coated nanospheres with different core compositions: effect on drug release kinetics
29. Compared bioavailability of IBP-5823 administered by the i.v. route in (i) stealth PLAPEG/cholate and (ii) non-stealth PLAGA/albumin nanoparticles
30. Ultradispersed polymer systems with rate and time control
31. Interactions de nanoparticules à base de poly(acides lactiques) avec les protéines plasmatiques de la coagulation
32. Encapsulation d'oligonucléotides dans des nanoparticules de Me-PEG-PLA50 après complexation avec des oligopeptides structurés
33. Solid dispersion and solid solution
34. Non phagocytic uptake of intravenously injected microspheres in rat spleen: influence of particle size and hydrophilic coating
35. Microparticulate systems for site-specific therapybone marrow targeting
36. Effect of the nonionic surfactant poloxamer 338 on the fate and deposition of polystyrene microspheres following intravenous administration
37. Dynamic light scattering of suspensions of PEO-coated latex particles. Colloids Surfaces, A: Physicochem
38. Contact angles of surfactants with a potential to alter the body distribution of colloidal drug carriers on poly(methyl methacrylate) surfaces
39. Biodistribution studies investigating poly(lactide-co-gly-colide) nanospheres surface modified by novel biodegradable copolymers
40. Polystyrene-poly(ethylene glycol) (PS-PEG2000) particles as model systems for site specific drug delivery. 2. The effect of PEG surface density on the in vitro cell interaction and in vivo biodistribution
41. Synthesis and characterization of a short-haired poly(ethylene oxide)-grafted polystyrene latex. Colloids Surfaces, A: Physicochem
42. Modification de la surface de nanoparticules de poly(cyanoacrylates d'alkyle) par greffage de poly-(éthylène glycol)
43. Block copolymer micelles as vehicles for drug delivery
44. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol
45. Interfacial photopolymerization of poly(ethylene glycol)-based hydrogels upon alginate poly(l-lysine) microcapsules for enhanced biocompatibility
46. Surface physical interpenetrating networks of poly(ethylene terephthalate) and poly(ethylene oxide) with biomedical applications
47. Effects of branching and molecular weight of surface-bound poly(ethylene oxide) on protein rejection
48. Preparation and surface properties of POE-sulfonate grafted polyurethanes for enhanced blood compatibility
49. Interactions of poly(ethylene glycol)-grafted cellulose membranes with proteins and platelets
50. Adsorption of proteins onto surfaces containing end-attached oligo(ethylene oxide) -a model system using self-assembled monolayers
51. Drug entrapment in liposomes
52. Therapy of leishmaniasis: superior efficacies of liposome-encapsulated drug
53. Activation of tumoricidal properties in monocytes from cancer patients following intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine
54. Increased circulatory half-life of liposomes after conjugation with dextran
55. Stealth liposomes: five years on
56. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo
57. R-lipid-lecithin mixtures
58. Factors affecting the clearance kinetics and tissue distribution of liposomes, microspheres and emulsions
59. Disintegration of phosphatidylcholine liposomes in plasma as a result of interaction with high-density lipoproteins
60. Laboratory synthesis of polyethylene glycol derivatives
61. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice
62. Hypothesis: why do polyethylene glycol-coated liposmes circulate so long?
63. Surface modification of nanoparticles by PEO/PPO block copolymers to minimize the interactions with blood components and prolong blood circulation in rats
64. Molecular mechanism of the lipid vesicle longevity in vivo
65. Increased circulatory half-life of liposomes after conjugation with dextran
66. Sterically stabilized liposomes
67. Protein-surface interactions in the presence of polyethylene oxyde. I. Simplified theory
68. Protein-surface interactions in the presence of polyethylene oxyde. II. Effect of protein size
69. Coating particles with a block copolymer (poloxamine 908) suppresses opsonisation but permits the activity of dysopsonins in the serum
70. The effect of block copolymers on the uptake of model polystyrene microspheres by Kupfer cells; in vitro and in vivo studies
71. Colloidal carriers for intravenous drug targeting-Determination of plasma protein adsorption patterns on surface-modified latex particles by two-dimensional polyacrylamide gel electrophoresis
72. Polylactic acid for surgical implants
73. Poly-dl-lactic acid polyethylene glycol block copolymers The influence of polyethylene glycol on the degradation of poly-dl-lactic acid
74. Melting behaviour of hydrolyzable poly(oxyethylene)/poly(l-lactide) copolymers
75. Morphological study of biodegradable PEO/PLA block copolymers
76. ESR spectroscopy as a probe of the morphology of hydrogels and polymer-polymer blends
77. Polylactones 22a) ABA triblock copolymers of l-lactide and poly(ethylene glycol)
78. Block copolymers from l-lactide and poly(ethylene glycol) through a non-catalyzed route
79. Super microcapsules (SMC). I. Preparation and characterization of star polyethylene oxide (PEO)-polylactide (PLA) copolymers
80. Synthesis and characterization of biodegradable ABA triblock copolymers consisting of poly(l-lactic acid) or poly(l-lactic-co-glycolic acid) attached to central poly(oxyethylene) B blocks
81. Synthèse et caractérisation de copolymères séquencés polyoxyéthylène/poly-ε-caprolactone
82. Biodegradable polymers for use in surgery-polyglycolic/poly(lactic acid) homo- and copolymers
83. Capronor: a biodegradable delivery system for levonorgestrel
84. Effects of soft segments and hydrolysis on the crystallization behaviour of degradable poly(oxyethylene)/poly(l-lactide) block copolymers
85. Biodegradable PELA copolymers: in vitro degradation and tissue reaction
86. Solute diffusion through degradable semicrystalline polyethylene glycol/poly(l-lactide) copolymers
87. Release rate of drugs from bioerodible microspheres made by using amphiphatic block copolymers
88. In vitro degradation and bovine serum albumin release of the ABA triblock copolymers consisting of poly(l(+)lactic acid), or poly(l(+) lactic acid-co-glycolic acid) A-blocks attached to central polyoxyethylene B-blocks
89. The preparation of sub-200 nm poly(lactide-co-glycolide) microspheres for site-specific drug delivery
90. The preparation of sub-200 nm biodegradable colloidal particles from poly(b-malic acid-co-benzyl malate) copolymers and their surface modification with Poloxamer and Poloxamine surfactants
91. Plasmaproteinadsorption auf kolloidalen Arzneistoffträgern
92. Protein adsorption to and elution from polyether surfaces
93. Complement activation by nanoparticulate carriers
94. Sequential imaging of Indium-111 labelled monoclonal antibody in human mammary tumors hosted in nude mice
95. Biodistribution of surface modified liposomes and particles
96. Liposomal gadolinium-DTPA: effect of encapsulation on enhancement of hepatome model by MRI